ARTICLE | Company News
BioTransplant cancer, autoimmune/inflammation, transplant news
August 5, 2002 7:00 AM UTC
BTRN reduced its headcount by 23%, as part of a restructuring program to focus on BTRN's AlloMune System to treat hematologic malignancies and Eligix HDM Cell Separation technology. The company said t...